Synaffix (Lonza)
Licensor of the GlycoConnect site-specific ADC conjugation platform, now part of Lonza and used by dozens of ADC developers.
GlycoConnect attaches payloads at the conserved Asn297 glycan for a defined DAR; HydraSpace and toxSYN complete the platform. Acquired by Lonza (2023) and integrated into an end-to-end ADC service; 2026 multi-target licences with Sidewinder (bispecific ADCs) and Engitix.
Pages like this
not linked directly; found by shared links- CompanyAbzena
Shares ADC bioconjugation manufacturing (CDMOs), Site-specific conjugation & linker chemistry.
- CompanyAraris Biotech (Taiho)
Shares Platform designation for ADC linker-payloads so manufacturing data carry across, Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TechnologyPayload-linker synthesis (high-potency API)
Shares Lonza, ADC bioconjugation manufacturing (CDMOs), Antibody-drug conjugate (ADC).
- CompanyTubulis (Gilead)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TermDrug-to-antibody ratio (DAR)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TechnologyAntibody manufacturing (CHO bioprocessing)
- ProductLuveltamab tazevibulin
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).